Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Holding CRVS?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.12Last Year’s EPS
-$0.14Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -42.58%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly for soquelitinib across various indications. However, financial challenges were evident with a substantial increase in net loss due to warrant liabilities.Company Guidance
During the Corvus Pharmaceuticals Q3 2024 earnings call, the executives provided detailed guidance on several key financial and clinical metrics. The company reported a research and development expense increase to $5.2 million from $4 million year-over-year due to heightened clinical trial costs for soquelitinib. They also experienced a significant net loss of $40.2 million, largely attributed to a noncash loss of $32.8 million from changes in warrant liability. Despite this, Corvus improved its cash position, holding $41.7 million, partly bolstered by $5.9 million from early warrant exercises, with potential for an additional $54 million. The company anticipates this cash will support operations into 2026. Clinically, Corvus is advancing soquelitinib in a Phase III trial for peripheral T-cell lymphoma and Phase I for atopic dermatitis, with initial data expected in December 2024. The trials aim to explore efficacy and safety at various dosing levels, with promising early indications of rapid response within the first week of treatment. Additionally, the company is pursuing opportunities in systemic sclerosis and other fibrotic diseases, leveraging soquelitinib's mechanism of action.Robust Cash Position and Financial Runway
Corvus had cash, cash equivalents, and marketable securities totaling $41.7 million as of September 30, 2024, compared to $27.1 million at December 31, 2023. The company anticipates its cash provides a runway into 2026.
Advancement in Clinical Trials for Soquelitinib
Soquelitinib Phase III trial for PTCL is enrolling patients, and a Phase I trial for atopic dermatitis is underway. The Phase I trial showed no safety signals in the initial cohort.
Strategic Collaborations and Designations for Soquelitinib
The FDA granted orphan drug and Fast Track designations for soquelitinib for relapsed T-cell lymphoma. The Phase III trial is enrolling at multiple prestigious sites.
Potential of Soquelitinib in Autoimmune Diseases
Preclinical data shows soquelitinib's activity in systemic sclerosis, and ongoing trials are exploring its potential in asthma, psoriasis, and other autoimmune diseases.
Progress with Ciforadenant in Collaborative Trials
The Phase Ib/II trial of ciforadenant in metastatic renal cell cancer is meeting statistical benchmarks, and new data suggests potential in prostate cancer.
---
CRVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $8.69 | $8.87 | +2.07% |
| Aug 06, 2024 | $3.00 | $3.29 | +9.67% |
| May 06, 2024 | $1.91 | $1.68 | -12.04% |
| Mar 19, 2024 | $1.96 | $1.85 | -5.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Corvus Pharmaceuticals Inc (CRVS) report earnings?
Corvus Pharmaceuticals Inc (CRVS) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Corvus Pharmaceuticals Inc (CRVS) earnings time?
Corvus Pharmaceuticals Inc (CRVS) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRVS EPS forecast?
CRVS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.12.
---